We are live on ! Find out more
ATOS icon

Atossa Therapeutics
ATOS

15 hedge funds and large institutions have $513K invested in Atossa Therapeutics in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more capital inflows, than outflows

Capital inflows: $57.8K | Capital outflows: $43.2K

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

7% more funds holding

Funds holding: 14 → 15 (+1)

0.08% more ownership

Funds ownership: 2.79% → 2.87% (+0.08%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
2
Closed
4
Calls
$24K
Puts
–
Net Calls
+$24K
Net Calls Change
-$19K

Top Buyers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
+$26.4K
2
JP Morgan Chase
JP Morgan Chase
New York
+$24K
3
Victory Capital Management
Victory Capital Management
Texas
+$3.45K
4
UBS Group
UBS Group
Switzerland
+$2.98K
5
Group One Trading
Group One Trading
Illinois
+$823

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$21.8K
2
Barclays
Barclays
United Kingdom
-$11.6K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$6K
4
Morgan Stanley
Morgan Stanley
New York
-$3.8K

ATOS Hedge Fund Activity: Q3 2019 in Review

15 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2019, worth a combined $513K — down 21% from $649K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ATOS positions and 4 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Northern Trust, opening a new position worth an estimated $26.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $21.8K sold.

  • 15 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2019, up from 14 in Q2 2019.
  • Funds reported $513K of Atossa Therapeutics stock for Q3 2019, down 21% quarter-over-quarter.
  • 5 funds opened new Atossa Therapeutics positions in Q3 2019 and 4 closed out, a net change of +1 holder.
  • The largest Atossa Therapeutics buyer in Q3 2019 was Northern Trust, an estimated $26.4K added.
  • The largest Atossa Therapeutics seller in Q3 2019 was Citadel Advisors, an estimated $21.8K sold.

Based on aggregated 13F filings for Q3 2019.